MannKind Corporation to Participate in the BTIG Virtual Biotechnology Conference 2021
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference on August 10, 2021, at 12:30 PM (ET).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference on August 10, 2021, at 12:30 PM (ET). This event is exclusive to BTIG clients. MannKind focuses on developing and marketing inhaled therapies for patients with endocrine and orphan lung diseases. Its leading product is Afrezza®, the only inhaled ultra-rapid-acting mealtime insulin available in the U.S. for prescription.
Details
News Market Reaction – MNKD
The recorded move for MNKD in the trading session of this news was -0.99%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTLAKE VILLAGE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat in the BTIG Virtual Biotechnology Conference 2021 on Tuesday, August 10, 2021 at 12:30 PM (ET).
BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra-rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil where it is commercialized by the Company’s partner Biomm SA. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility in Danbury, Conn. The Company also employs field sales and medical representatives across the U.S. Please visit www.mannkindcorp.com to learn more.
MANNKIND CONTACT:
Rose Alinaya, Investor Relations
Phone: (818) 661-5000
Email: ir@mannkindcorp.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.